Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluids.
about
Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4)Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sitesMatrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP)Membrane-type 1 MMP (MMP-14) cleaves at three sites in the aggrecan interglobular domainAggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.Catabolism of aggrecan, decorin and biglycan in tendon.Biglycan and fibromodulin have essential roles in regulating chondrogenesis and extracellular matrix turnover in temporomandibular joint osteoarthritis.Mechanical load inhibits IL-1 induced matrix degradation in articular cartilageThe use of cleavage site specific antibodies to delineate protein processing and breakdown pathways.Matrix metalloproteinases are not essential for aggrecan turnover during normal skeletal growth and development.Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member.ADAMTS4 cleaves at the aggrecanase site (Glu373-Ala374) and secondarily at the matrix metalloproteinase site (Asn341-Phe342) in the aggrecan interglobular domain.Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage.The accumulation of intracellular ITEGE and DIPEN neoepitopes in bovine articular chondrocytes is mediated by CD44 internalization of hyaluronan.Osteoarthritis year 2010 in review: biochemical markers.Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repairThe role of aggrecan in normal and osteoarthritic cartilage.Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent.Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage.Proteoglycomics: recent progress and future challenges.Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns. Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity.Protein degradation fragments as diagnostic and prognostic biomarkers of connective tissue diseases: understanding the extracellular matrix message and implication for current and future serological biomarkers.Bioactivity in an Aggrecan 32-mer Fragment Is Mediated via Toll-like Receptor 2.Aggrecan: A Target Molecule of Autoimmune Reactions.Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activityThe 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases.Characterization of helical cleavages in type II collagen generated by matrixins.Host metalloproteinases in Lyme arthritis.Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro.N-linked keratan sulfate in the aggrecan interglobular domain potentiates aggrecanase activity.Evidence of a novel aggrecan-degrading activity in cartilage: Studies of mice deficient in both ADAMTS-4 and ADAMTS-5.Aggrecanase cleavage in juvenile idiopathic arthritis patients is minimally detected in the aggrecan interglobular domain but robust at the aggrecan C-terminus.Investigating ADAMTS-mediated aggrecanolysis in mouse cartilage.Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation.An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2.MMP proteolysis of the human extracellular matrix protein aggrecan is mainly a process of normal turnover.Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants.Differential Expression of Aggrecanase and Matrix Metalloproteinase Activity in Chondrocytes Isolated from Bovine and Porcine Articular CartilageSerum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis
P2860
Q22253473-5DF92C63-75F3-4061-A7AE-716980FC753DQ28138661-90A2D8B2-AB94-4A98-A616-91C625D21B3AQ28142482-484B2CB0-2805-488F-97A3-2DEC83BA1437Q28278203-02C73DE6-8DA4-44F7-894C-27A2ED4D2A1AQ30807179-28E38D44-8F08-48A5-8078-6E7ECEE5D26DQ30894356-AB20893A-2219-4F73-852B-5E7A594A3326Q33597165-E7DF41BC-7CE4-4AAB-BC49-0F316F2D3273Q33636776-67BBE8E7-01F1-495E-90ED-503C19B36877Q33706655-8CC2D944-25DC-4CD0-B65E-7D2165E5B242Q33724459-D7E01452-8AEC-45ED-864C-562A1B4D555CQ33901135-ADD52736-3A80-4E68-B54F-C872701F603BQ34114956-D88E52D6-3F99-49CF-B4F8-94896DDF60CFQ34123993-7D888B29-2F7F-4D83-A647-B5B141C62B31Q34569288-C6FBBE11-5BD6-43E6-A816-39CC03FBA22AQ34728871-BE911356-7875-4DD7-B94D-E38DB0F52F6EQ35785741-C9765FB4-D89F-404E-91E4-349EBBBE3075Q36289587-65EF2DA5-BBE3-4681-989F-08B655013A41Q37361470-D463724F-1F89-4D60-B2E4-38CFD21E809BQ37365557-91ADF1F3-4449-43D5-BB6A-C0184A5BA41AQ37745062-3AC41787-7758-4DBC-AC3F-C4CD772E4940Q38307518-3C221415-B400-491E-A1A4-F5902695E67FQ38675211-8F0AF415-684A-442C-8E8A-DE41A9F2F7D5Q38906815-42B1C049-2CA7-4FED-B17A-0FA50EDC679BQ39263919-8FB194FF-0450-4830-9F9D-320FD838D6C3Q40886514-D995F5A8-1B6E-43F8-A83C-678FD3B32F0EQ41881350-4CEDF5C9-6363-4C16-BEAC-19BDE591EBDCQ41952330-E58FA630-28D7-45CF-92BC-1929C086B53CQ43641032-0536AAEB-0282-4AA9-86D5-12C2F715FE53Q44183277-A0A903C1-52D6-42B6-81A5-4DD65C18C59EQ46453456-0F2795C2-8258-4EF4-A6F8-67F780DFFB32Q46567549-AEFE4125-D750-48A1-9E8C-242A01A392A7Q50242889-C4F6156D-2C88-4E84-9006-B5C047E6D85BQ50280462-FB99F660-6EE3-4E23-A4D9-69DCCBD54CB1Q50469418-5F497E71-9E92-4C83-97A3-78A5B2B82326Q52725144-1EAD3B9B-D923-4649-9153-1ECF4F5A69CDQ53164462-DA244682-2AE3-409E-8D68-57E5DCC7F0E1Q54045457-8EF155C8-6699-47FD-8F3F-9775EE365035Q57539960-08B686E6-5234-46CD-A080-959857649FCCQ58715277-C58471C9-59A3-4393-803D-218D5E41AD38
P2860
Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluids.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Development of a cleavage-site ...... ents in human synovial fluids.
@en
Development of a cleavage-site ...... ents in human synovial fluids.
@nl
type
label
Development of a cleavage-site ...... ents in human synovial fluids.
@en
Development of a cleavage-site ...... ents in human synovial fluids.
@nl
prefLabel
Development of a cleavage-site ...... ents in human synovial fluids.
@en
Development of a cleavage-site ...... ents in human synovial fluids.
@nl
P2093
P2860
P356
P1433
P1476
Development of a cleavage-site ...... ents in human synovial fluids.
@en
P2093
P2860
P304
P356
10.1042/BJ3100337
P407
P478
310 ( Pt 1)
P577
1995-08-01T00:00:00Z